GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

GLP Receptor Related Products (201)
Antibodies (1)

By Effects:	Inhibitors (16) Agonists (126) Degraders (2) Controls (2) Ligand (1) Antagonists (8) Activators (13) Modulators (8) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P4610

H-Trp-Tyr-OH	Activator	99.43%
H-Trp-Tyr-OH is an orally active tryptophan-tyrosine dipeptide with blood-brain barrier permeability. H-Trp-Tyr-OH exerts physiological regulatory effects by stimulating enteroendocrine cells to secrete glucagon-like peptide GLP-1. In mouse models of tauopathies, H-Trp-Tyr-OH inhibits tau phosphorylation, reduces the level of neurofibrillary tangles, increases dopamine turnover, upregulates synapsin expression, and elevates cecal short-chain fatty acid levels, thereby improving behavioral deficits and extending lifespan. H-Trp-Tyr-OH can be used in research related to impaired glucose tolerance and tauopathies.

HY-171850

GLP-1R modulator-1	Agonist
GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

HY-P0014A

Liraglutide acetate	Agonist
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes.

HY-P10842

d-GLP-2 E33A	Agonist
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC₅₀ of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases.

HY-P11487

UTG-4	Agonist
UTG-4 is a GLP-1R, GIPR, and GCGR agonist with EC₅₀ values of 126.3 pM, 29.2 pM, and 250.2 pM, respectively. UTG-4 binds to HSA (K_d = 14.6 μM). UTG-4 effectively alleviates endothelial-mesenchymal transition. UTG-4 promotes weight loss, inhibits food intake, improves glucose tolerance, and has a significant anti-atherosclerotic effect.

HY-182502

GLP-1R-agonist-43	Agonist
GLP-1R-agonist-43 (Compound A) is an orally active GLP-1R agonist with an EC₅₀ of 2.68 nM. GLP-1R-agonist-43 can be used in the research of non-insulin-dependent diabetes mellitus (type 2 diabetes) and obesity.

HY-178769

GLP-1R agonist 36	Agonist
GLP-1R agonist 36 (Compound 53) is a GLP-1R agonist with a total of four isomers. GLP-1R agonist 36 can be used for the studies of diabetes and obesity.

HY-176838

LXT34
LXT34 (Example 2) is a GPR120 agonist. LXT34 has an anti-inflammatory activity. LXT34 promotes GLP-1 formation in the gastrointestinal tract and improves insulin resistance in macrophages and pancreas cells. LXT34 can be used for inflammatory diseases, such as type 2 diabetes, obesity and non-alcoholic fatty liver research.

HY-162434

GLP-1R agonist 42	Agonist
GLP-1R agonist 42 is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0122 nM.

HY-P11279

TC2	Agonist
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes.

HY-P11667

Erzemdutide	Agonist
Erzemdutide is a glucagon and glucagon-like peptide 1 (GLP-1) receptor agonist. Erzemdutide can be used for the study of obesity.

HY-114118F5

Semaglutide, Cy5 labeled	Agonist
Semaglutide, Cy5 labeled is a CY5 (HY-D0821) labeled Semaglutide (HY-114118), which is suitable for high-sensitivity fluorescence detection and imaging (Ex/Em = 633/670 nm).

HY-P11235

Berobenatide	Agonist
Berobenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.

HY-W701772

2-Oleoylglycerol-d₅
2-Oleoylglycerol-d₅ (2-OG-d₅) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-161915

GLP-1R agonist 23	Agonist
GLP-1R agonist 23 (Example 376) is a GLP-1R agonist with an EC₅₀ of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research.

HY-147626

GLP-1R agonist 13	Agonist
GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist.

HY-10289A

Carmegliptin hydrochloride	Activator
Carmegliptin hydrochloride (RO-4876904 hydrochloride) is an orally active and potent DPP‑IV inhibitor with a human DPP‑IV IC₅₀ of 6.8 nM. Carmegliptin hydrochloride binds to the S1 pocket of DPP‑IV, blocks the degradation of GLP‑1, potentiates endogenous GLP‑1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin hydrochloride acts as a substrate for human P‑glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin hydrochloride can be used for the research of type 2 diabetes, non‑insulin‑dependent diabetes mellitus.

HY-P4389

(Asp28)-Glucagon (1-29) (human, rat, porcine)	Activator
(Asp28)-Glucagon (1-29) (human, rat, porcine) is an optimized structure of glucagon, the 28th position is replaced by aspartic acid (Asp) which significantly increases the aqueous solubility of glucagon in a physiological pH buffer, has the same activity as glucagon.

HY-170516

GLP-1 receptor agonist 16	Agonist
GLP-1 receptor agonist 16 (Example 53) is a GLP-1 agonist. GLP-1 receptor agonist 16 can be used for the research of diabetes, obesity, or nonalcoholic steatohepatitis-related diseases^[1].

HY-173479

GLP-1R agonist 30	Agonist
GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC₅₀ of 0.048 nM. GLP-1R has excellent selectivity, with EC₅₀ greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.

GLP Receptor

GLP Receptor Related Products (201)

Antibodies (1)

GLP Receptor Related Products (201):